Novartis Bioventures Ltd 4
4 · BICYCLE THERAPEUTICS plc · Filed May 30, 2019
Insider Transaction Report
Form 4Exit
Novartis Bioventures Ltd
10% Owner
Transactions
- Conversion
Ordinary Shares
[F1]2019-05-28+893,195→ 893,195 total - Exercise of In-Money
Ordinary Shares
[F1]2019-05-28+71,450→ 964,645 total - Conversion
Ordinary Shares
[F1]2019-05-28+636,366→ 1,601,011 total - Purchase
Ordinary Shares
2019-05-28$14.00/sh+168,630$2,360,820→ 1,769,641 total - Conversion
Series A Preferred Shares
[F1]2019-05-28−893,195→ 0 total→ Ordinary Shares (893,195 underlying) - Exercise of In-Money
Series A Preferred Shares Warrants
[F2][F1]2019-05-28−71,450→ 0 total→ Ordinary Shares (71,450 underlying) - Conversion
Series B1 Preferred Shares
[F1]2019-05-28−636,366→ 0 total→ Ordinary Shares (636,366 underlying)
Footnotes (2)
- [F1]Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.